IBT-B.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 09:56):

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden...

Stats
Today's Volume	22 057.00
Average Volume	6 544.00
Market Cap	1.30B
EPS	SEK0 ( 2024-05-06 )
Next earnings date	( SEK0 ) 2024-08-28
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-9.97
ATR14	SEK0.660 (0.66%)

Infant Bacterial Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Infant Bacterial Financials

Annual	2023
Revenue:	SEK77 000.00
Gross Profit:	SEK77 000.00 (100.00 %)
EPS:	SEK-9.95

FY	2023
Revenue:	SEK77 000.00
Gross Profit:	SEK77 000.00 (100.00 %)
EPS:	SEK-9.95

FY	2022
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-5.80

FY	2021
Revenue:	SEK0.00
Gross Profit:	SEK0.00 (0.00 %)
EPS:	SEK-0.429

Financial Reports:

No articles found.

Infant Bacterial Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Infant Bacterial

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.